key: cord-0857603-76rn2f0t
authors: Muthukrishnan, J.; Vardhan, Vasu; Mangalesh, Sridhar; Koley, Mrinalini; Shankar, Subramanian; Yadav, Arun Kumar; Khera, Anurag
title: Vaccination status and COVID-19 related mortality: A hospital based cross sectional study
date: 2021-07-26
journal: Med J Armed Forces India
DOI: 10.1016/j.mjafi.2021.06.034
sha: 1d059e552375ceb001d56098584a9389aa965918
doc_id: 857603
cord_uid: 76rn2f0t

BACKGROUND: Efficacy of vaccines studied in clinical trial settings are likely to be different from their effectiveness in a real-world scenario. Indian Armed Forces launched its vaccine drive against COVID-19 on 16 Jan 2021. This study evaluated the effect of vaccination on mortality amongst hospitalized COVID patients. METHODS: A cross sectional study was done on all admitted moderate to severe COVID-19 patients at a designated COVID hospital in New Delhi. The primary outcome assessed the association of being fully vaccinated with mortality. Unadjusted odds ratios (OR) (with 95% CI) was performed for each predictor. Logistic regression was used for multivariable analysis and adjusted odds ratios obtained. RESULTS: The 1168 patients included in the study had a male preponderance with a mean age of 54.6 (± 17.51) years. A total of 266 (23%) patients were partially vaccinated with COVISHIELD® and 184 (16%) were fully vaccinated. Overall, 518 (44.3%) patients had comorbidities and 332 (28.4%) died. Among those fully vaccinated, there was 12.5% (23/184) mortality while it was 31.45 % (309/984) among the unvaccinated (OR 0.3, 95% CI 0.2 to 0.5, p<0.0001). In a logistic regression model, complete vaccination status and younger age were found to be associated with survival. CONCLUSIONS: Vaccination with two doses of COVISHIELD® was associated with lower odds of mortality among hospitalized patients with moderate to severe COVID.

Immunity against SARS-CoV-2 virus causing COVID-19, achieved after infection, was shown to be variable in its duration and efficacy. 1, 2 Vaccines studied in trials were noted to achieve significant immunity in both previously infected and naïve subjects and varied from 92% for documented infection, 87% for hospitalization, and 92% for severe disease. 3e7 The second wave of the pandemic in India, beginning March 2021, had patients presenting in larger numbers with more severe disease at hospitals. At the same time, as part of the vaccination drive that was started w.e.f 16 Jan 2021, most healthcare and frontline workers of the Indian Armed Forces had been vaccinated with COVISHIELD® (manufactured by Serum institute of India pvt ltd, Pune, India). COVISHIELD (ChAdOx1 nCoV-19) is an adenovirus vector-nonreplicating virus vaccine carrying recombinant spike protein of SARS-CoV-2. The process of vaccinating its elderly (>65yrs) clientele and those above 45 years with comorbidities was being undertaken thereafter.

Studies had shown various factors to be associated with mortality in COVID-19. 8e12 We wanted to study the association of vaccination status with COVID-19 related mortality and hypothesized that the vaccination against SARS-COV-2 infection would be associated with a lower mortality due to COVID-19 infection in hospitalised patients.

The present record-based cross-sectional study was conducted in a 1000-bedded tertiary care hospital. A total of 2620 cases of SARS-CoV-2 infection, admitted between 01 March to 17 May 2021, comprised the population from where the study sample was selected.

Cases of RTPCR confirmed SARS-CoV-2 infection with moderate to severe illness as per the IDSA criteria for severity of COVID-19 (Resp rate >24/min and SPO2<94% on room air, at rest or after 6-min walk test) were admitted during the study period. 13 Patient records were reviewed to obtain clinical and demographic data. A data extraction form was designed. The data on age, sex, comorbid conditions, and vaccination status was extracted. Dates of vaccination, symptom onset, laboratory confirmation of the diagnosis, hospital admission, and clinical outcome were recorded. The individuals were deemed partially vaccinated and fully vaccinated two weeks after the first and second dose respectively. The total duration of hospitalisation was calculated till the primary outcome (Death/ Discharge). Patients were discharged at least ten days from onset of symptoms and being afebrile >72h irrespective of RT-PCR status and SPO2>94% on room air (sustained for more than 24 h) or with RT-PCR negative status with clinical recovery. Patients with RT-PCR negative status with oxygen requirement that could be met using domiciliary oxygen therapy were transferred to another center for institutional care.

To select parameters for sample size calculation, we looked at data from a similar hospital. SVBP Hospital at New Delhi, operationalised on 19 April 21 for second wave of COVID-19, was managed by Armed Forces Doctors for Civilians and had similar admission criteria as our hospital. A total of 1479 patients had been admitted till 15 May 21, of which 38.7% died. About 5% of all admissions had received 2 doses (personal communication). During the same period in New Delhi, 85% of healthcare workers and 42% of those above 45 years of age had received 1 dose of vaccine with a fourth of them (~23%) having received two doses. 14, 15 In the Armed Forces, over 85% of health care workers and frontline workers had received both doses by mid May. The vaccination drive among families aged >45 years and veterans was also higher than their civilian counterparts. Therefore, we estimated that at least 10% (likely between 12 and 15%) of all admitted cases were likely to have received both doses of vaccine in our hospital. Vaccine effectiveness data with COVISHIELD had shown between 80 and 88% reduction in hospitalisation. 1, 16 Mortality reduction was close to 100% in the primary vaccine efficacy study. 17 We estimated our sample size based on the following assumptions; namely, 10% of all admitted patients would have received two doses of vaccine and the expected overall mortality would be 25%. Those having received two doses would have 12.5% mortality (50% reduction) than unvaccinated patients. Sample size was calculated using online calculator (sample-size.net by UCSF) taking a ¼ 0.05 and a power of 80%. The required sample size was 984 and we included 1168 patients in our study. Institutional ethical clearance was obtained.

Data was compiled in a rectangular format on spreadsheet. Continuous variables were expressed as mean ± standard deviation (SD) and categorical variables as percentages. Unadjusted odds ratios (OR) (with 95% CI) were estimated to determine the association of vaccination status, age, sex, and the presence of comorbidities with mortality. Multivariable logistic regression was done to adjust for confounding variables and adjusted OR obtained. Statistical analysis was per- 

The hospital saw a total of 2620 admissions during the second wave of COVID-19 from 01 Mar to 17 May 2021. Cases with milder disease (n ¼ 561), were transferred to an isolation facility. Of the remaining, a total of 1716 patients had either died or had been discharged and 343 were still in hospital at the m e d i c a l j o u r n a l a r m e d f o r c e s i n d i a 7 7 ( 2 0 2 1 ) S 2 7 8 eS 2 8 2 end of the study period. The study sample was selected randomly from the study population of 1716 patients.

The patients included in the study comprised 1168 patients with a mean age of 54.6 (SD-17.5) years ( Table 1 ). The age wise distribution of deaths is shown in Fig. 1 Other conditions included coronary artery disease (16%), hypothyroidism (12.4%), malignancies (9.8%), bronchial asthma (5.2%), chronic kidney disease (3.9%), chronic obstructive pulmonary disease (3.7%), and stroke (2.7%).

Multivariable logistic regression was done for adjustment of age, sex and co-morbidities. The adjusted odds ratio for fully vaccinated vs unvaccinated was 0.5 (95% CI 0.3e0.8, p ¼ 0.004) while the adjusted odds ratio for partially vaccinated and un-vaccinated was 0.8 (95% CI 0.6e1.1, p ¼ 0.1) ( Table 2 ). In multivariable analysis in three groups (Unvaccinated, partially vaccinated, and full vaccinated), age was significantly associated with mortality with unit rise in age associated with 6% (OR 1.06; 95% CI 1.05e1.08) increase in unvaccinated/partially vaccinated and 15% (OR 1.15; 95% CI 1.1e1.2) increase in fully vaccinated persons.

Our study showed that being fully vaccinated and younger age were associated with lower mortality. The overall mortality amongst those who were hospitalized with severe COVID-19 was 28.4%. This was consistent with the fact that only moderate to severe patients were admitted requiring high flow oxygen or ventilation. Various studies in the literature have examined the predictors of mortality in patients with Age and comorbidities (especially diabetes mellitus and hypertension) have most commonly been shown to be Fig. 1 e Age distribution of death and discharged cases. 

associated with death. 9 We noted greater mortality in those aged >65 years, and this increase was despite their vaccination status. Amongst the comorbidities, the greatest risk of increased mortality has been documented with diabetes mellitus. 11 Diabetes mellitus and hypertension were the commonest comorbidities in our study. We did not analyse for individual comorbidities in our study and instead looked at the presence of comorbidities as an independent variable. Studies have also shown that disease severity scores and the degree of the rise of inflammatory markers are associated with higher risk of mortality. 18 Since our study included only patients with severe COVID-19 disease, we did not study the degree of disease severity or markers of inflammation as mortality predictors.

Most of the predictive studies had been performed when vaccination against COVID-19 had not been instituted. Earlier studies from trials and real world data has shown that vaccinated persons are less likely to have the asymptomatic or symptomatic disease and less hospitalization due to severe disease. 2, 6, 13, 19 Data obtained from the vaccine effectiveness studies for the Astra Zeneca (ChAdOx1 nCoV-19) vaccine have shown upto 80% reduction in hospitalization. 16 More realworld studies were needed to assess vaccine status as a predictor of mortality. 20, 21 Being well powered with a large sample size, our study showed a significant association of being fully vaccinated with lower mortality status among hospitalized patients. COVISHIELD® has been shown to reduce infections by 80e94%. 1, 22 In present study the fully vaccinated individuals have 70% lower odds of mortality than unvaccinated persons among hospitalized severe cases.

There are several limitations to this study as is to be expected in any cross sectional design. Though we did show association between mortality and vaccination status, causality cannot be inferred. Ideally, one needs to follow large natural cohorts of vaccinated vs unvaccinated and see actual infection/mortality rates. 2, 19, 23 Some of the survivors might have succumbed to post COVID-19 complications at a later point in time post discharge and thus might have been misclassified. The survivors were significantly younger and had fewer comorbidities and the vaccination pattern was skewed. However, despite these limitations, the effect of vaccination status was demonstrable on multivariable logistic regression analysis.

There is a need to do further research to confirm the role of vaccination status in mitigating other predictors of mortality due to severe COVID-19. There is also the need to study the relationship between immunogenicity and vaccine effectiveness in subgroups like elderly and diabetics where mortality is the highest.

In conclusion, this is one of the earliest real life vaccine studies that showed that being fully immunized with COV-ISHIELD® vaccine, was associated with lower mortality among those hospitalized with severe COVID-19 infection. Findings of this study reconfirms the need to vaccinate as many persons as possible at the earliest to successfully face the future wave of COVID-19.

The authors have none to declare. r e f e r e n c e s 

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting

Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet

Predicting COVID-19 Mortality with Electronic Medical Records

Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease

Predictors of mortality in patients with COVID-19ea systematic review

Predictors of In-Hospital COVID-19 Mortality: A Comprehensive Systematic Review and Meta-Analysis Exploring Differences by Age, Sex and Health Conditions

Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Sci Rep

Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19

Epub ahead of print

Covid: Vaccination Of Frontline Workers In Delhi Below National Average: Centre

42% of 45þ age vaccinated in Delhi so far, centres remain shut for 18-44 age group for fourth day -Cities News

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Efficacy estimates for various COVID-19 Vaccines : what we know from the literature and reports

Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Evaluation of COVID-19 Vaccine Effectiveness

Use of the case-control approach in vaccine evaluation: efficacy and adverse effects

Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

COVID-19 dynamics after a national immunization program in Israel